Navigation Links
ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
Date:12/17/2009

='External Link';s.eVar3=s.prop5;s.prop15='79490252';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.anadyspharma.com/">www.anadyspharma.com. A telephone replay with slides will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 75270153. The webcast and telephone replay will be available through December 31, 2009.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to (i) the expected timing for enrolling the next cohort in the ANA598 Phase II study and for receiving 12 week data from the 200 mg bid cohort and 4 and 12 week data from the 400 mg bid cohort; (ii) the prospects of ANA598 being able to contribute to long-term treatment outcome as measured by SVR and the hope that ANA598 will be established as the leading non-nucleoside in HCV, suitable for combination with current SOC as well as with other direct antivirals currently in development; (iii) the ability for patients to achieve EVR and SVR in the ANA598 Phase II study; and (iv) assessments of the safety and tolerability profile of ANA598 based on the interim 4 week analysis. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 will not have unforeseen safety issues or will continue to have favorable results as the Phase II trial progresses. In addition, Anadys' results may be affected by competition from other biotechno
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
11. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting ... China,s orthopedic instrument industry has ... size rising from 3.28 billion yuan in 2006 to ...
(Date:1/15/2014)... AARP Foundation today announced it has established a ... severe cold weather that has gripped much of the nation. ... need; so to support these emergency relief efforts AARP and ... could mean up to $500,000 in aid. The matching program ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today ... Friday, June 17, 2011. At the meeting, shareholders approved the ... to increase the total number of authorized shares and authorized ... Therapeutics, Inc. Headquartered in Seattle, CTI ...
... 17, 2011 Unilife Corporation ("Unilife" or the ... Kathleen Merrigan, the Deputy Secretary of the U.S. Department of ... local business leaders at its facility in York, Pennsylvania. ... (WHBC) under the direction of President Obama. The Winning ...
Cached Medicine Technology:Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders 2Unilife Hosts White House Business Council Meeting 2Unilife Hosts White House Business Council Meeting 3
(Date:4/18/2014)... A new article published online in The ... to religious music is associated with a decrease in ... and sense of control over their lives. In particular, ... in anxiety about death and an increase in sense ... and whites, women and men, and individuals of both ...
(Date:4/18/2014)... 2014) Benaroya Research Institute at Virginia Mason (BRI) ... particular molecule in metastatic breast cancer reduces both the ... metastases. BRI scientists have found in models of the ... 60 - 80 percent and can keep the tumor ... million five-year grant comes from the National Cancer Institute ...
(Date:4/18/2014)... A discovery by Northwestern Medicine scientists could lead to ... scarring in people with scleroderma. , Fibrosis, or ... tightening of the skin and lungs can lead to ... The concept for new therapeutic options centers on findings ... Medicine-Rheumatology, who identified the role that a specific protein ...
(Date:4/17/2014)... targets that could be used to provide relief ... London made the discovery when researching how pain ... body. , Dr Marzia Malcangio said: "We have ... and our findings could help chemotherapy patients who ... side effect of some chemotherapy drugs (such as ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2
... YORK, Feb. 12 Medicare now pays for treatments ... change that and apply a cost-effectiveness standard set by ... Effectiveness Research.The Federal Council is modeled after a U.K. ... This British board approves or rejects treatments using ...
... damage, and study says it,s likely all that sugar , , THURSDAY, ... cans of soda pop daily are almost two times more likely ... to a U.S. study. , But there,s no increased risk for ... drink diet soda. , The researchers analyzed data from 9,358 adults ...
... The Final Inch and Slumdog Millionaire show the challenges ... Astute Oscar-watchers are getting a short ... nominated films that together show the status of this ... four countries where the virus has not been stopped. ...
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today announced it ... 19, 2009, and will host a conference call to discuss these ... , , , Date: Thursday, February ... Conference call access:, Internet: www.istavision.com, ...
... got radiation treatment for Hodgkin,s disease are almost 40 times ... findings from five institutions, including the University of Florida. ... researchers report. These women are also likely to develop cancer ... get rid of the cancer. Our second priority is to ...
... Pamper Tired TootsiesBETHESDA, Md., Feb. 12 Valentine,s Day marks ... men and women. While the old adage "a way to ... true, another body part is gaining affection from both sexes ... (APMA) survey revealed 84 percent of women are embarrassed about ...
Cached Medicine News:Health News:2 or More Sodas a Day Boost Women's Kidney Risks 2Health News:Oscar Nominated Films Raise Polio Awareness 2Health News:Pediatric Hodgkin's disease survivors face increased breast cancer risk 2Health News:Pediatric Hodgkin's disease survivors face increased breast cancer risk 3Health News:American Podiatric Medical Association Helps Americans 'Love' Their Feet This Valentine's Day 2Health News:American Podiatric Medical Association Helps Americans 'Love' Their Feet This Valentine's Day 3
... Excaliburplus PC, 100V, 50Hz/60Hz is the most ... V PTP in spray Coag. It is the ... power settings from the surgical field with a ... Output Voltage in CUT maintains minimum necessary voltage ...
Microprocessor-based isolated electrosurgical generator, designed for all general surgical procedures. Unit includes the Valleylab adaptive REM system and Instant Response technology....
Black multi-pinhole occluder...
6 inch hand held occlcuder with 49 holes...
Medicine Products: